Page last updated: 2024-10-31

moclobemide and Depressive Disorder, Major

moclobemide has been researched along with Depressive Disorder, Major in 13 studies

Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research Excerpts

ExcerptRelevanceReference
"For new MAO-A inhibitors, about 74% occupancy at steady-state dosing is desirable."2.76Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. ( Houle, S; Meyer, JH; Parkes, J; Rusjan, P; Sacher, J; Sagrati, S; Wilson, AA, 2011)
"From a clinical point of view, orthostatic hypotension is a significant side effect during antidepressant treatment, particularly in the case of tricyclic antidepressants (TCAs)."2.71Orthostatic side effects of clomipramine and moclobemide during treatment for depression. ( Stage, KB, 2005)
"Sertraline was well tolerated."2.69An open study of sertraline in patients with major depression who failed to respond to moclobemide. ( Chiu, E; George, T; Hokin, A; Krapivensky, N; Theodoros, MT; Tiller, JW, 1999)
" A metaregression did not reveal a statistically significant relation between the mean moclobemide dosage for each study and the risk ratio for response rates."2.43A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. ( Fava, M; Papakostas, GI, 2006)
"Treatment-resistant depression is a major depressive disorder that does not respond to adequate treatment of at least two antidepressants and is one of the major clinical challenges for clinicians and clinical pharmacists."1.43Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case. ( Oravecz, R; Stuhec, M, 2016)
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."1.42Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)
"Moclobemide has negative immunoregulatory capacities through inhibition of the production of proinflammatory cytokines, i."1.31The in vitro immunosuppressive effects of moclobemide in healthy volunteers. ( Bosmans, E; De Jongh, R; Kenis, G; Lin, A; Maes, M; Scharpé, S; Song, C, 2000)
"Musical hallucinations are the hearing of tunes, melodies, harmonics, rhythms and timbres."1.31Musical hallucinations associated with abruptly developed bilateral loss of hearing. ( Ozçürümez, G; Sayilgan, MA; Tanriverdi, N, 2001)
" This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic."1.31Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. ( Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's8 (61.54)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hayasaka, Y1
Purgato, M1
Magni, LR1
Ogawa, Y1
Takeshima, N1
Cipriani, A1
Barbui, C1
Leucht, S1
Furukawa, TA1
Stuhec, M1
Oravecz, R1
Sacher, J1
Houle, S1
Parkes, J1
Rusjan, P1
Sagrati, S1
Wilson, AA1
Meyer, JH1
Bech, P1
Stage, KB2
Larsen, JK1
Vestergaard, P1
Gram, LF1
Henkel, V1
Mergl, R1
Allgaier, AK1
Kohnen, R1
Möller, HJ1
Hegerl, U1
Papakostas, GI1
Fava, M1
Jimenez-Genchi, A1
George, T1
Theodoros, MT1
Chiu, E1
Krapivensky, N1
Hokin, A1
Tiller, JW1
Lin, A1
Song, C1
Kenis, G1
Bosmans, E1
De Jongh, R1
Scharpé, S1
Maes, M1
Bekaroğlu, M1
Değer, O1
Karahan, SC1
Bilici, M1
Soylu, C1
Orem, A1
Tanriverdi, N1
Sayilgan, MA1
Ozçürümez, G1
Vanderkooy, JD1
Kennedy, SH1
Bagby, RM1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463]Phase 288 participants (Anticipated)Interventional2021-07-18Recruiting
Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome[NCT05174273]Phase 2/Phase 3180 participants (Anticipated)Interventional2022-04-06Recruiting
A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224]Phase 2/Phase 335 participants (Actual)Interventional2018-01-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for moclobemide and Depressive Disorder, Major

ArticleYear
Treatment of depression with atypical features: a meta-analytic approach.
    Psychiatry research, 2006, Jan-30, Volume: 141, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Moclobemide; Monoami

2006
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:12

    Topics: Depressive Disorder, Major; Disorders of Excessive Somnolence; Fatigue; Headache; Humans; Imipramine

2006

Trials

4 trials available for moclobemide and Depressive Disorder, Major

ArticleYear
Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
    Journal of psychiatry & neuroscience : JPN, 2011, Volume: 36, Issue:6

    Topics: Adult; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Female; Harmine; Humans; Hypericum;

2011
The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine.
    Journal of affective disorders, 2012, Volume: 140, Issue:3

    Topics: Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder, Major; Double-Blind Method; Fem

2012
Orthostatic side effects of clomipramine and moclobemide during treatment for depression.
    Nordic journal of psychiatry, 2005, Volume: 59, Issue:4

    Topics: Adult; Aged; Antidepressive Agents; Clomipramine; Depressive Disorder, Major; Drug Administration Sc

2005
An open study of sertraline in patients with major depression who failed to respond to moclobemide.
    The Australian and New Zealand journal of psychiatry, 1999, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Rel

1999

Other Studies

7 other studies available for moclobemide and Depressive Disorder, Major

ArticleYear
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
    Journal of affective disorders, 2015, Jul-15, Volume: 180

    Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose

2015
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.
    Wiener klinische Wochenschrift, 2016, Volume: 128, Issue:7-8

    Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Dru

2016
Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11

    Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Duloxetine Hydrochloride; Fema

2006
The in vitro immunosuppressive effects of moclobemide in healthy volunteers.
    Journal of affective disorders, 2000, Volume: 58, Issue:1

    Topics: Adult; Antidepressive Agents; Cytokines; Depressive Disorder, Major; Female; Humans; Immune Toleranc

2000
Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression.
    Journal of affective disorders, 2000, Volume: 59, Issue:3

    Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Maj

2000
Musical hallucinations associated with abruptly developed bilateral loss of hearing.
    Acta psychiatrica Scandinavica, 2001, Volume: 103, Issue:2

    Topics: Adult; Atrophy; Brain; Depressive Disorder, Major; Electroencephalography; Female; Hallucinations; H

2001
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan

2002
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan

2002
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan

2002
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan

2002